FTC’s Take On Two Pharma Mergers Shows Deals Can Clear Higher Hurdle
Executive Summary
Pfizer’s acquisition of Arena without FTC intervention and Hikma’s acquisition of Custopharm with one product divestiture shows the commission is bound by anticompetitive facts of a deal. A more controversial merger may not get through, former FTC attorney says.
You may also be interested in...
FTC Objections To Pharma Mergers Could Go Unchallenged Following Wilson’s Resignation
The commission no longer has a voice opposing aggressive antitrust enforcement actions and President Biden's replacement may be more receptive to the stance of the three current Democratic commissioners. Amgen’s proposed acquisition of Horizon is facing FTC scrutiny.
Political Trials On All Sides: Lilly CEO Laments Loss Of ‘Chamber of Commerce Republicans’
David Ricks says the challenging political environment is empowering regulators. The Lilly leader also talked Twitter and drug prices, in a STAT Summit interview.
FTC’s New Commissioner, Alvaro Bedoya, May Bolster Tougher Stance On Pharma Oversight
Democrats gain majority on Federal Trade Commission with Bedoya’s swearing in. His positions on technology and digital privacy suggest he will align with commissioners who have advocated stricter review of pharma mergers.